STOCK TITAN

Myriad Genetics Inc - MYGN STOCK NEWS

Welcome to our dedicated news page for Myriad Genetics (Ticker: MYGN), a resource for investors and traders seeking the latest updates and insights on Myriad Genetics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Myriad Genetics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Myriad Genetics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.53%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
partnership
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.83%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.92%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
none
Myriad Genetics Inc

Nasdaq:MYGN

MYGN Rankings

MYGN Stock Data

1.76B
74.68M
2.01%
103.03%
6.3%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SALT LAKE CITY

About MYGN

myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.